Fintepla is a drug owned by Zogenix Inc. that contains the active ingredient fenfluramine hydrochloride. It first hit the market on 25 June, 2020. The drug is available in solution;oral dosage forms and has a total of 24 patents.
The generic version of Fintepla could be available after the expiry of the last patent on 29 December, 2038.
Fintepla is primarily used for the treatment of refractory epilepsy patients with fenfluramine, which reduces the risk of cardiovascular toxicity by using cardiac monitoring and restricted distribution. The drug is also used in combination with other drugs such as cannabidiol, stiripentol, valproate, and clobazam for the treatment of seizures associated with Dravet syndrome and Lennox Gastaut syndrome.
Fintepla, with the active ingredient Fenfluramine Hydrochloride, is protected by 24 patents. The patents cover aspects from methods of treatment to formulation techniques. The most recent patent protecting Fintepla generic will expire on 29 December, 2038. Below are the details of the patent: